Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-02-04 | Mr. Clark has been a Strategic Advisory Board member of Genstar Capital, LLC since August 2007 and was an Operating Partner from August 2007 to January 2013. Genstar Capital LLC is a middle market private equity firm that focuses on investments in selected segments of life sciences and healthcare services, industrial technology, business services and software. Prior to that, Mr. Clark was the Chief Executive Officer and President of ICOS Corporation, a biotherapeutics company, from June 1999 to January 2007, and the Chairman of the Board of Directors of ICOS from February 2000 to January 2007. |
| 2017-02-02 | Mr. Clark was a Strategic Advisory Board member of Genstar Capital, LLC from August 2007 to December 2016 and was an Operating Partner from August 2007 to January 2013. Genstar Capital LLC is a middle market private equity firm that focuses on investments in selected segments of life sciences and healthcare services, industrial technology, business services and software. Prior to that, Mr. Clark was the Chief Executive Officer and President of ICOS Corporation, a biotherapeutics company, from June 1999 to January 2007. |
| 2018-02-08 | Mr. Clark has significant experience in the pharmaceutical and biotechnology industries, including his experience serving in senior management positions with ICOS Corporation, Abbott Laboratories, Marion Laboratories and Sandoz Pharmaceuticals. In addition, Mr. Clark brings considerable public company director experience as well as his extensive experience within our industry and expertise in business finance. |
| 2019-02-07 | Mr. Clark was a Strategic Advisory Board member of Genstar Capital, LLC... Mr. Clark has significant experience in the pharmaceutical and biotechnology industries... Mr. Clark is the chairperson of our Audit and Finance Committee and is qualified as a financial expert under SEC guidelines. |
| 2020-02-06 | Mr. Clark has significant experience in the pharmaceutical and biotechnology industries, including his experience serving in senior management positions. |
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-07 | Mr. Clark was appointed to the Board of Directors in February 2014 and serves as Chairman of the Board and the Chairman of our Nominating and Corporate Governance Committee. ... Mr. Clark is currently a member of the board of directors of Agilent Technologies, Inc., Chairman of the Board of Keysight Technologies, and Chairman of the Board of Cerevast Therapeutics, Inc. ... Mr. Clark brings to our Board extensive experience within our industry and expertise in business finance. |
| 2016-09-07 | Paul N. Clark is Chairman of the Board of the Company. |
| 2017-04-05 | Mr. Clark was appointed to our Board in February 2014 and serves as Chairman of the Board and Chairman of our Nominating and Corporate Governance Committee. ... Mr. Clark received a Bachelor of Arts degree in Finance from the University of Alabama and a Master of Business Administration degree from Dartmouth College. Mr. Clark brings to our Board extensive experience within our industry and expertise in business finance. ... The following table sets forth all compensation earned or paid to our non-employee directors during the year ended December 31, 2016. ... Paul N. Clark ... Total $350,698 ... The Audit Committee currently consists of Messrs. Clark and Talevich and Dr. Moll. Mr. Talevich serves as its Chairman. ... The Compensation Committee currently consists of Mr. Clark and Dr. Lord. ... The Nominating and Corporate Governance Committee currently consists of Messrs. Clark and Talevich and Drs. Lord and Moll. Mr. Clark serves as its Chairman. |
| 2017-05-19 | Paul N. Clark Chairman of the Board The following table sets forth the beneficial ownership of shares of our common stock as of May 18, 2017 by (i) each current director, (ii) each named executive officer and (iii) all current directors and executive officers as a group. Paul N. Clark is the Chairman of the Board of the Company. |
Data sourced from SEC filings. Last updated: 2026-02-03